The Longevity Science Foundation has extended its Invested in Her crowdfunding campaign to 1 October, seeking $250,000 for early-stage research into ovarian aging and menopause, with $64,667 raised and a $25,000 match from LongeVC contingent on reaching the target. Funds are allocated across three linked areas: precise measurement of reproductive aging, mechanistic work on how ovarian decline drives systemic aging, and interventions including gene therapy and partial epigenetic reprogramming. The campaign highlights a persistent funding gap between scientific rationale and commercial readiness in female healthspan research.
Key Points
- Campaign extended to October; $64,667 raised toward $250,000 target
- Funding covers measurement, mechanism and intervention in ovarian aging
- Proposed "menopause clock" would track reproductive biomarkers beyond symptom history
Longevity Analysis
Ovarian decline precedes and plausibly accelerates changes in cognition, metabolism and vascular function, making reproductive aging one of the earliest measurable signals of systemic decline rather than a fertility endpoint. A validated biological clock for menopause would replace symptom reporting and menstrual history with quantifiable markers, allowing intervention during the window when hormonal signaling still shapes tissue maintenance and repair. The bottleneck here is capital rather than concept — promising mechanistic work stalls before it reaches the validation threshold that attracts conventional investment.
Original published by Longevity.Technology, by Eleanor Garth.